MedTrace Logo

Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care

NCT03937245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3058

Last updated 2021-09-09

No results posted yet for this study

Summary

Eurobact II will investigate the mortality and morbidity of hospital-acquired blood stream infections in patients treated in intensive care units (ICU). It will investigate the effects of the micro-organism and its characteristics, such as type and resistance to antibiotics on the infection and its consequences. It will also investigate the effects of the antibiotics and other treatments on survival of patients. Eurobact II will include patients from multiple ICUs in multiple countries.

Conditions

  • Bacteremia
  • Sepsis
  • Hospital Acquired Condition
  • Resistance Bacterial

Sponsors & Collaborators

  • European Society of Intensive Care Medicine

    collaborator OTHER

  • European Society of Clinical Microbiology and Infectious Diseases

    collaborator OTHER

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • Outcome Rea

    lead OTHER

Principal Investigators

  • Alexis Tabah, MD · ICU, Redcliffe Hospital, Faculty of Medicine, UQ, Brisbane, QLD, Australia.

  • Jean-Francois Timsit, MD,PhD · Medical and infectious diseases ICU, Bichat hospital, IAME U 1137,Paris,France

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-30
Primary Completion
2021-06-02
Completion
2021-06-03

Countries

  • Australia
  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03937245 on ClinicalTrials.gov